Da-Chaihu-Tang alters the pharmacokinetics of nifedipine in rats and a treatment regimen to avoid this.
Ju-Xiu He, Kenji Ohno, Jun Tang, Masao Hattori, Tadato Tani, Teruaki Akao
Index: J. Pharm. Pharmacol. 66(11) , 1623-30, (2014)
Full Text: HTML
Abstract
To investigate the influence of co-administrated Da-Chaihu-Tang (DCT; a traditional Chinese formulation) on the pharmacokinetics of nifedipine, as well as the safe optimal dosing interval to avoid the adverse interactions.A single dose of DCT was administered with nifedipine simultaneously, 2 h before, 30 min before or 30 min after nifedipine administration. Pharmacokinetics of nifedipine with or without DCT were compared. The influences of DCT on nifedipine intestinal mucosal and hepatic metabolism were studied by using rat in-vitro everted jejunal sac model and hepatic microsomes.A simultaneous co-administration of DCT significantly increased the area under concentration-time curve from time zero to infinity (AUC0-inf ) of nifedipine. In-vitro mechanism investigations revealed that DCT inhibited both the intestinal and the hepatic metabolism of nifedipine. Further study on the optimal dosing interval for nifedipine and DCT revealed that administration of DCT 30 min before or after nifedipine did not significantly change the AUC of nifedipine.The bioavailability of nifedipine is significantly increased by a simultaneous oral co-administration of DCT. This increase is caused by the inhibitory effect of DCT on both the intestinal mucosal and the hepatic metabolism of nifedipine. The dose interval between DCT and nifedipine needs to be set for over 30 min to avoid such drug-drug interactions.© 2014 Royal Pharmaceutical Society.
Related Compounds
Related Articles:
2003-04-01
[Mol. Pharmacol. 63(4) , 784-90, (2003)]
2014-01-01
[PLoS ONE 9(4) , e94885, (2014)]
Interactions of endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells.
2014-08-01
[Drug Metab. Dispos. 42(8) , 1235-40, (2014)]
Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.
2014-01-01
[Biol. Pharm. Bull. 37(11) , 1727-35, (2014)]
2014-01-01
[PLoS ONE 9(9) , e106769, (2014)]